A prospective randomized multicentre study of the impact of gallium‐68 prostate‐specific membrane antigen (PSMA) PET/CT imaging for staging high‐risk prostate cancer prior to curative‐intent surgery or radiotherapy (proPSMA study): clinical trial protocol
Open accessThe DOI matches its Crossref record.
Abstract
Background: Accurate staging of patients with prostate cancer ( PC a) is important for therapeutic decision‐making. Relapse after surgery or radiotherapy of curative intent is not uncommon and, in part, represents a failure of staging with current diagnostic imaging techniques to detect disease spread. Prostate‐specific membrane antigen ( PSMA ) positron‐emission tomography ( PET )/computed tomography ( CT ) is a new whole‐body scanning technique that enables visualization of PC a with high contrast. The hypotheses of this study are that: (i) PSMA ‐ PET / CT has improved diagnostic performance compared with conventional imaging; (ii) PSMA ‐ PET / CT should be used as a first‐line diagnostic test for staging; (iii) the improved diagnostic performance of PSMA ‐ PET / CT will result in significant management impact; and (iv) there are economic benefits if PSMA ‐ PET / CT is incorporated into the management algorithm. Objectives and Methods: The pro PSMA trial is a prospective, multicentre study in which patients with untreated high‐risk PC a will be randomized to gallium‐68‐ PSMA ‐11 PET / CT or conventional imaging, consisting of CT of the abdomen/pelvis and bone scintigraphy with single‐photon emission CT / CT . Patients eligible for inclusion are those with newly diagnosed PC a with select high‐risk features, defined as International Society of Urological Pathology grade group ≥3 (primary Gleason grade 4, or any Gleason grade 5), prostate‐specific antigen level ≥20 ng/mL or clinical stage ≥T3. Patients with negative, equivocal or oligometastatic disease on first line‐imaging will cross over to receive the other imaging arm. The primary objective is to compare the accuracy of PSMA ‐ PET / CT with that of conventional imaging for detecting nodal or distant metastatic disease. Histopathological, imaging and clinical follow‐up at 6 months will define the primary endpoint according to a predefined scoring system. Secondary objectives include comparing management impact, the number of equivocal studies, the incremental value of second‐line imaging in patients who cross over, the cost of each imaging strategy, radiation exposure, inter‐observer agreement and safety of PSMA ‐ PET / CT . Longer‐term follow‐up will also assess the prognostic value of a negative PSMA ‐ PET / CT . Outcome and Significance: This trial will provide data to establish whether PSMA ‐ PET / CT should replace conventional imaging in the primary staging of select high‐risk localized PC a, or whether it should be used to provide incremental diagnostic information in selected cases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Hofman, M. S., Lawrentschuk, N., Francis, R. J., Tang, C., Vela, I., Thomas, P., Rutherford, N., Martin, J. M., Frydenberg, M., Shakher, R., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30314-7 · Cited by 2,040
Self-citationPerera, M., Papa, N., Roberts, M., Williams, M., Udovicich, C., Vela, I., Christidis, D., Bolton, D., Hofman, M. S., Lawrentschuk, N., et al. (2020) · European Urology · doi:10.1016/j.eururo.2019.01.049 · Cited by 958
Self-citationGillessen, S., Attard, G., Beer, T. M., Beltran, H., Bossi, A., Bristow, R., Carver, B., Castellano, D., Chung, B. H., Clarke, N., et al. (2018) · European Urology · doi:10.1016/j.eururo.2017.06.002 · Cited by 642
PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0
Fendler, W. P., Eiber, M., Beheshti, M., Bomanji, J., Calais, J., Ceci, F., Cho, S. Y., Fanti, S., Giesel, F. L., Goffin, K., et al. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-06089-w · Cited by 410
Gillessen, S., Attard, G., Beer, T. M., Beltran, H., Bjartell, A., Bossi, A., Briganti, A., Bristow, R. G., Chi, K. N., Clarke, N., et al. (2020) · European Urology · doi:10.1016/j.eururo.2020.01.012 · Cited by 389
Self-citationUpdates to Advanced Prostate Cancer: AUA/SUO Guideline (2023)
Lowrance, W., Dreicer, R., Jarrard, D. F., Scarpato, K. R., Kim, S. K., Kirkby, E., Buckley, D. I., Griffin, J. C., & Cookson, M. S. (2023) · Journal of Urology · doi:10.1097/ju.0000000000003452 · Cited by 321
“Abiraterone acetate plus prednisone, enzalutamide, and docetaxel chemotherapy all have an FDA indication for use in men with mCRPC.”
BackgroundInfluentialViolet, J., Sandhu, S., Iravani, A., Ferdinandus, J., Thang, S.-P., Kong, G., Kumar, A. R., Akhurst, T., Pattison, D., Beaulieu, A., et al. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.236414 · Cited by 292
Self-citationConsensus statements on PSMA PET/CT response assessment criteria in prostate cancer
Fanti, S., Goffin, K., Hadaschik, B. A., Herrmann, K., Maurer, T., MacLennan, S., Oprea-Lager, D. E., Oyen, W. J., Rouvière, O., Mottet, N., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04934-4 · Cited by 214
“PSMA PET/CT is considered a potentially useful tool for evaluating responses to therapy, but there is lack of data regarding criteria to be used for evaluating PSMA PET/CT findings in relation to therapy response assessment [2, 4].”
MethodResultIravani, A., Violet, J., Azad, A., & Hofman, M. S. (2020) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-019-0174-x · Cited by 68
Self-citation
Metadata
- Authors
- Hofman, M. S., Murphy, D. G., Williams, S. G., Nzenza, T., Herschtal, A., Lourenco, R. D. A., Bailey, D. L., Budd, R., Hicks, R. J., Francis, R. J., & Lawrentschuk, N.
- Venue
- BJU International
- Publisher
- Wiley
- Published
- 2018-06-03
- Volume
- 122
- Issue
- 5
- Pages
- 783-793
- ISSN
- 1464-4096 (ISSN-L)
- 1464-410X
- OpenAlex
- W2799328879
- Cited by
- 121
- References
- 0
- FWCI
- 12.85
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.